Inhibrx is a privately held, science-first, self-sustainable biotherapeutic company. Inhibrx developed an efficient and productive scientific and business approach to align the incentives of our scientific team, collaborators, biotech and pharmaceutical partners and investors to rapidly develop transformative therapeutics for patients in need.
Mark Lappe, Founder
Chief Executive Officer
Mark founded Inhibrx with Brendan Eckelman and Quinn Deveraux in 2010 and served as the Chief Executive Officer since the companyâ€™s inception. »
Brendan Eckelman, Ph.D., Founder
Chief Operating Officer & VP of Biotherapeutics
Brendan leads biotherapeutic development and scientific operations at Inhibrx. He oversees multiple groups, including discovery, protein sciences and biology. »
Quinn Deveraux, Ph.D., Founder
Chief Scientific Officer
Quinn leads the target identification, validation and therapeutic lead selection and oversees the development strategy for Inhibrxâ€™s biotherapeutic pipeline. »
Klaus W. Wagner, M.D., Ph.D.
Chief Medical Officer
Klaus leads the clinical translation of Inhibrxâ€™s biotherapeutic pipeline. Prior to joining Inhibrx, Klaus trained at M.D. Anderson Cancer Center as a fellow and worked at Banner M.D. Anderson »
Matthew Cohen, J.D.
Matt leads legal affairs at Inhibrx. Prior to joining Inhibrx, Matt served as Senior Vice President, General Counsel and Corporate Secretary of GenMark Diagnostics. »
John Timmer, Ph.D.
VP of Research
John leads single domain antibody discovery projects and biotherapeutic development at Inhibrx. He has been instrumental in developing Inhibrx's multispecific antibody formats for conditional immune activation. »